MOUNTAIN VIEW, Calif., March 13 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Yuying Gao, M.D., Ph.D., Senior Scientist, will speak to members of the Japanese pharmaceutical industry attending the 28th mini-symposium of the Department of Molecular Pharmacokinetics, to be held at the University of Tokyo on March 23, 2006.
Dr. Gao will give a presentation on the strategic value of quantitative modeling and simulation to support regulatory submission, along with panelists from industry and academia, as part of a university-sponsored symposium entitled, “The Role of PK/PD Simulation in Drug Development: Is it Possible to Link the Simulation to the Regulatory Science?” The session will include applications of modeling and simulation to support key decisions, and will describe research on how “in silico” methods and technology have been used to predict pharmacokinetics in humans, treatment strategies, and drug-drug interactions. The session will also offer a forum for interdisciplinary discussion on the utility of model-based drug development in the drug approval process. Additional information can be found at http://www.f.u-tokyo.ac.jp/index-e.html.
“PK/PD modeling and simulation continue to gain currency as a valuable set of methods for improving the quality and value of drug development decisions,” said Shawn O’Connor, President and CEO of Pharsight. “Exposure-response modeling and trial simulation are essential tools in today’s global development environment, particularly where model-based insights can be leveraged to explore new treatment strategies and serve new patient populations. We are pleased to see growing interest in Pharsight’s capabilities in the Japanese market, and Pharsight is pleased to participate in this distinguished gathering at the University of Tokyo to exchange information and best practices on the strategic application of modeling and simulation.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or press, Steve DiMattia, +1-646-277-8706, allof EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com//
